Overview of VUR

The retrograde ascent of urine from the bladder into the ureter has been vaguely known since the discovery by the scientists Leonardo DaVinci and Galen in the 15th century. However, the pathophysiology of VUR (vesicoureterorenal reflux) in the pyelocaliceal system, renal parenchyma (intrarenal reflux) and renal function have only been known since the 1960s and 70s, with the malformation of the reflux-protective ureterovesical junction also known and diagnosed as a causative factor.

VUR – timely treatment!
The importance of timely reflux treatment can be recognized from the fact that untreated reflux can lead to terminal renal insufficiency requiring hemodialysis. Reflux nephropathy is the leading cause of renal insufficiency in children and adolescents.

Endoscopic treatment with CRM ® VURDEX
Based on the knowledge that late treatment or untreated reflux can, in the worst case scenario, result in total kidney failure, we would like to present you this brochure describing CRM ® VURDEX, a hyaluronic acid gel for endoscopic injections of the ostium, as an alternative to surgical reflux remediation: CRM ® VURDEX

Overview of VUR

What is CRM ® VURDEX?

Product formulation
CRM ® VURDEX is a gel based on hyaluronic acid, which essentially consists of two ingredients, positively charged dextranomer and a specially prepared, cross-linked hyaluronic acid of non-animal origin.

Content / 1 ml:
Cross-linked sodium hyaluronate 10.0 mg
Dextranomer      20.0 mg
Sodium chloride 6.9 mg
Water for injection 1.0 ml

Excellent absorption into the tissue
Both components are composed of polysaccharides (molecules based on glucose). These synthetically produced ingredients are so similar to those of the human body that they are accepted without further modification, and can be integrated in and processed by the tissue.

Biocompatibility of CRM ® VURDEX
In addition, the components of CRM ® VURDEX are biocompatible and well tolerated because they are of non-animal origin. That is, they are produced synthetically in the laboratory under strict purity requirements, so that the risk of allergic reactions is minimized.

Positively charged dextranomer
BioScience has gone one step further with the development of CRM ® VURDEX. Collagenase is demonstrably stimulated by the use of positively charged dextranomer. Collagen is an essential part of the skeletal and connective tissue and thus supports the remission or maturation of valve function.

Only outstanding product features make the best treatment results possible.
Therefore, with CRM ® VURDEX, BioScience has developed an injection substance with optimal properties for minimally invasive treatment of VUR.

These properties include:

  • Easy to use
  • High success rate
  • Minimum load for young patients
  • Excellent tissue compatibility
  • Reliable retention at the injection site
  • Long-term retention at the injection site

Hienlohestr. 24 | 83624 Otterfing
Deutschland / Germany

Tel: +49 8024 99 27 0
Fax: +49 8024 99 27 27

EMail: info@coordmed.de